Myriad Genetics announces RiskScore study results published

Myriad Genetics announced that Genetics in Medicine, an official journal of the American College of Medical Genetics and Genomics, or ACMG, published a new study validating RiskScore, Myriad’s breast cancer risk assessment tool integrated into its MyRisk Hereditary Cancer Test. RiskScore combines a polygenic risk score, or PRS, validated for all ancestries with the Tyrer-Cuzick model, a widely used breast cancer risk assessment calculator. The study – first shared as a Spotlight Presentation at the 2022 San Antonio Breast Cancer Symposium – examined real-world patient outcomes from more than 130,000 women who have taken Myriad’s MyRisk Hereditary Cancer Test with RiskScore. The study demonstrated that RiskScore was more accurate at stratifying women at high- or low-risk of developing breast cancer than the Tyrer-Cuzick risk calculator alone. In fact, the integration of RiskScore with Tyrer-Cuzick improved predictive accuracy by roughly two-fold over Tyrer-Cuzick alone.